Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Nuvigil

- PMLiVE

Change at the top as Levin leaves Teva

CEO resigns amid company-wide restructure

- PMLiVE

EMA backs Lundbeck’s Brintellix in depression

Drug recommended for approval to treat major depressive episodes in adults

- PMLiVE

Ariad tanks as Iclusig trial is halted on safety grounds

Shares fall after leukaemia patients develop blood clots

- PMLiVE

Union pressure delays Teva’s Israeli layoffs

Workforce cuts put on hold

- PMLiVE

Teva cuts 5,000 jobs to save $2bn a year by 2017

Israeli pharma company accelerates cost-reduction plans

- PMLiVE

Teva defends Copaxone from Dutch patent challenge

Halts Mylan from marketing generic copy of MS drug

- PMLiVE

Teva signs R&D alliance to pursue novel cancer drugs

Will work with Cancer Research on first-in-class oncology treatments

Bristol-Myers Squibb (BMS) building

BMS’ Yervoy fails prostate cancer trial

Unable to improve overall survival in phase III

- PMLiVE

Setback for GSK as melanoma vaccine misses targets

Cancer immunotherapy disappoints in phase III

- PMLiVE

Amgen drug misses endpoint in acute heart failure trial

Company pledges to pursue development of omecamtiv mecarbil in chronic heart failure

- PMLiVE

Teva halts development of Nuvigil in bipolar disorder

Shelves plan to expand use of sleep disorder therapy

Bristol-Myers Squibb (BMS) building

BMS drops antidepressant in phase IIb

Liafensine no better than Lilly’s Cymbalta

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links